Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $65 price target.
June 18, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $65 price target.
The reiteration of an Overweight rating and a maintained price target of $65 by a reputable analyst from Cantor Fitzgerald is likely to positively impact investor sentiment and could lead to a short-term increase in NTLA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100